Mirum Pharmaceuticals (MIRM) Defended by Second Outlet, This time from Evercore: 'we think the move down is noise in a volatile tape this morning.'
Tweet Send to a Friend
Evercore ISI analyst Gavin Clark-Gartner reiterated an Outperform rating and $101.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
